Antibodies directed against amyloid-beta peptide and methods using same
First Claim
Patent Images
1. A method for treating a disease characterized by aberrant deposition of β
- -amyloid in a subject, comprising administering to the subject an effective amount of an antibody that specifically binds to a β
-amyloid peptide or an aggregated form of a β
-amyloid peptide(Aβ
), wherein the antibody comprises a heavy chain variable region comprising;
(a) a CDR1 comprising the amino acid sequence of SEQ ID NO;
3;
(b) a CDR2 comprising the amino acid sequence of SEQ ID NO;
4; and
(c) a CDR3 comprising the amino acid sequence of SEQ ID NO;
5;
and a light chain variable region comprising;
(d) a CDR1 comprising the amino acid sequence of SEQ ID NO;
6;
(e) a CDR2 comprising the amino acid sequence of SEQ ID NO;
7; and
(f) a CDR3 comprising the amino acid sequence of SEQ ID NO;
8.
1 Assignment
0 Petitions
Accused Products
Abstract
Monoclonal antibody 9TL and antibodies derived from 9TL directed against amyloid-beta peptide and methods of using same for diagnosing and treatment of Alzheimer'"'"'s disease and Aβ peptide associated diseases are described. Methods of using antibodies directed against amyloid-beta peptide having impaired effector function for treatment of Alzheimer'"'"'s disease and Aβ peptide associated diseases are also described.
150 Citations
68 Claims
-
1. A method for treating a disease characterized by aberrant deposition of β
- -amyloid in a subject, comprising administering to the subject an effective amount of an antibody that specifically binds to a β
-amyloid peptide or an aggregated form of a β
-amyloid peptide(Aβ
), wherein the antibody comprises a heavy chain variable region comprising;(a) a CDR1 comprising the amino acid sequence of SEQ ID NO;
3;(b) a CDR2 comprising the amino acid sequence of SEQ ID NO;
4; and(c) a CDR3 comprising the amino acid sequence of SEQ ID NO;
5;and a light chain variable region comprising; (d) a CDR1 comprising the amino acid sequence of SEQ ID NO;
6;(e) a CDR2 comprising the amino acid sequence of SEQ ID NO;
7; and(f) a CDR3 comprising the amino acid sequence of SEQ ID NO;
8.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)
- -amyloid in a subject, comprising administering to the subject an effective amount of an antibody that specifically binds to a β
-
34. A method for treating a disease associated with aberrant deposition of β
- -amyloid in a subject, comprising administering to the subject an effective amount of an antibody that specifically binds to a β
-amyloid peptide or an aggregated form of a β
-amyloid peptide, wherein the antibody comprises an Fc region with a variation from a naturally occurring Fc region, wherein the variation results in impaired effector function, and further wherein the antibody comprises a heavy chain variable region comprising;(a) a CDR1 comprising the amino acid sequence of SEQ ID NO;
3;(b) a CDR2 comprising the amino acid sequence of SEQ ID NO;
4; and(c) a CDR3 comprising the amino acid sequence of SEQ ID NO;
5; and
a light chain variable region comprising;(d) a CDR1 comprising the amino acid sequence of SEQ ID NO;
6;(e) a CDR2 comprising the amino acid sequence of SEQ ID NO;
7; and(f) a CDR3 comprising the amino acid sequence of SEQ ID NO;
8. - View Dependent Claims (35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)
- -amyloid in a subject, comprising administering to the subject an effective amount of an antibody that specifically binds to a β
-
56. A method for treating Alzheimers disease in a subject, comprising administering to the subject an effective amount of an antibody that specifically binds to a β
- -amyloid peptide, wherein the antibody comprises a heavy chain variable region comprising;
(a) a CDR1 comprising the amino acid sequence of SEQ ID NO;
3;(b) a CDR2 comprising the amino acid sequence of SEQ ID NO;
4; and(c) a CDR3 comprising the amino acid sequence of SEQ ID NO;
5; and
a light chain variable region comprising;(d) a CDR1 comprising the amino acid sequence of SEQ ID NO;
6;(e) a CDR2 comprising the amino acid sequence of SEQ ID NO;
7; and(f) a CDR3 comprising the amino acid sequence of SEQ ID NO;
8. - View Dependent Claims (57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)
- -amyloid peptide, wherein the antibody comprises a heavy chain variable region comprising;
Specification